Clinical Trial – The Benefit and Harm of Fever Suppression by Antipyretics in Influenza – Flu

The study is a double-blind, randomized controlled trial. Four hundred young adults aged 18-30 years will be recruited when they present with symptoms of acute respiratory infection within 48 hours of symptoms onset to university health clinics, and being tested positive with a QuickVue rapid influenza test. They will receive their clinical consultation and prescriptions as indicated as usual, and being randomized to receive either paracetamol or placebo, and given back-up NSAID for intolerable fever when required. Blood specimen, nasal and throat swabs will be collected on the same day (day 1). They will be followed-up on day 4, day 7 and day 10 for further collection of nasal and throat swabs, and on day 28 for a final blood taking. A symptom diary will be kept by each participant for 10 days for monitoring the clinical course of the infection.

Study Type  : Interventional  (Clinical Trial)
Estimated Enrollment  : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial on the Effect of Fever Suppression by Antipyretics on Influenza
Actual Study Start Date  : July 2013
Estimated Primary Completion Date  : December 2018
Estimated Study Completion Date  : December 2018

 

Contacts
Contact: Teresa HC So (+852) 39176714 haso9150@hku.hk

 

ClinicalTrials.gov Identifier: NCT01891084
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.